0.0975GBp-99.00%Mkt Cap: 25.27M GBpP/E: —Last update: 2026-05-29
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, a…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap25.27M GBp
Enterprise Value21.32M GBp
Revenue (TTM)4.64M GBp
Gross Profit2.86M GBp
Net Income (TTM)-696.25K GBp
Revenue/Share0.0200 GBp
Last Price0.0975 GBp
Fiscal Year EndJun 2025
MR QuarterJun 2025
Employees41
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)51.59
PEG—
EV/EBITDA-26.03
EV/Revenue4.60
P/S5.45
P/B2.71
EPS (TTM)0.00
EPS (Forward)0.00
52W Range
0.09750% of range23.00
52W High23.00 GBp
52W Low0.0975 GBp
Profitability
Gross Margin61.65%
Oper. Margin-2.86%
EBITDA Margin-17.65%
Profit Margin-15.01%
ROE-7.39%
ROA-5.74%
Growth
Revenue Growth177.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.24M GBp
CapEx (TTM)158.83K GBp
FCF Margin-34.90%
FCF Yield-6.41%
Net Debt-3.79M GBp
Net Debt/EBITDA4.62
Balance Sheet
Debt/Equity0.11
Current Ratio4.84
Quick Ratio4.21
Book Value/Sh0.0360 GBp
Cash/Share0.0180 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)29.00 GBp
Target Range29.00 GBp – 29.00 GBp
# Analysts1
Ownership
Shares Out.259.17M
Float143.36M
Insiders38.85%
Institutions14.31%
Technical
SMA 504.137 (-97.6%)
SMA 20012.31 (-99.2%)
Beta0.13
S&P 52W Chg27.94%
Avg Vol (30d)0
Avg Vol (10d)0
Technical Indicators
RSI (14)57.9
MACD1.9385
MACD Signal1.2447
MACD Hist.+0.6938
BB Upper14.83 GBp
BB Middle4.924 GBp
BB Lower-4.9795 GBp
BB Width402.26%
ATR (14)2.054 GBp
Vol Ratio (20d)—